§ Mr. Staintonasked the Secretary of State for Social Services what clinical results have so far been established in 576W respect of the drug Proplex; and if this is yet regarded as suitable for home treatment of haemophiliacs under the National Health Service.
§ Mr. MoyleProplex is on the market in the United Kingdom. A product licence was granted after consideration of the results of clinical trials in the United States of America. Proplex is indicated for use in the treatment of Christmas disease (haemophilia B): it is inappropriate for the treatment of the commoner form of haemophilia, haemophilia A. It may also be useful in the haemorrhagic conditions of the newborn and in coagulation disorders associated with hepatic disease. It is at present available only from specialised haemophilia centres and is normally administered under medical supervision. It is administered by intravenous injection, and the question of home treatment is a matter for the doctor concerned.